# Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

> **NCT02861573** · PHASE1,PHASE2 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1200 (estimated)

## Conditions studied

- Metastatic Castration-Resistant Prostate Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab 200 mg
- **DRUG:** Olaparib 400 mg
- **DRUG:** Docetaxel 75 mg/m^2
- **DRUG:** Prednisone 5 mg
- **DRUG:** Enzalutamide 160 mg
- **OTHER:** Dexamethasone 8 mg
- **DRUG:** Olaparib 300 mg
- **DRUG:** Abiraterone acetate 1000 mg
- **DRUG:** Lenvatinib
- **BIOLOGICAL:** Pembrolizumab/Vibostolimab coformulation
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **BIOLOGICAL:** Belzutifan 120mg

## Key facts

- **NCT ID:** NCT02861573
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2016-11-17
- **Primary completion:** 2027-10-22
- **Final completion:** 2028-07-24
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02861573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02861573, "Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT02861573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*